Royalty Pharma
RPRX
590 hedge funds and large institutions have $17B invested in Royalty Pharma in 2026 Q1 according to their latest regulatory filings, with 117 funds opening new positions, 224 increasing their positions, 181 reducing their positions, and 59 closing their positions.
188% more call options, than puts
Call options by funds: $42.8M | Put options by funds: $14.9M
98% more first-time investments, than exits
New positions opened: 117 | Existing positions closed: 59
24% more repeat investments, than reductions
Existing positions increased: 224 | Existing positions reduced: 181
23% more capital invested
Capital invested by funds: $13.8B → $17B (+$3.18B)
9% more funds holding
Funds holding: 539 → 590 (+51)
0% more funds holding in top 10
Funds holding in top 10: 14 → 14 (0)
0.92% less ownership
Funds ownership: 83.73% → 82.8% (-0.92%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$352M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$171M |
| 3 |
Royal London Asset Management
United Kingdom
|
+$159M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$98.6M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$75.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$513M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$187M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$114M |
| 4 |
Jane Street
New York
|
-$112M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$57.1M |
RPRX Hedge Fund Activity: Q1 2026 in Review
590 of the 8,137 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q1 2026, worth a combined $17B — up 23% from $13.8B a quarter earlier.
Buyers outnumbered sellers: 117 funds opened new RPRX positions and 59 closed out — a net gain of 58 holders — while 224 added to existing stakes and 181 trimmed.
The largest buyer was Capital World Investors, opening a new position worth an estimated $352M. The largest seller was Morgan Stanley, cutting an estimated $513M.
- 590 institutional investors held Royalty Pharma (RPRX) as of Q1 2026, up from 539 in Q4 2025.
- Funds reported $17B of Royalty Pharma stock for Q1 2026, up 23% quarter-over-quarter.
- 117 funds opened new Royalty Pharma positions in Q1 2026 and 59 closed out, a net change of +58 holders.
- The largest Royalty Pharma buyer in Q1 2026 was Capital World Investors, an estimated $352M added.
- The largest Royalty Pharma seller in Q1 2026 was Morgan Stanley, an estimated $513M sold.
Based on aggregated 13F filings for Q1 2026.